Therapeutic Effect of Polidocanol Sclerotherapy on Oral Vascular Malformations

Abstract

Various treatments for oral vascular malformation (VM) have been reported. Polidocanol and absolute ethanol have also been reported for sclerotherapy. However, there are still few reports on the therapeutic effect and dosage of polidocanol sclerotherapy. Therefore, we examined its therapeutic effects on oral VM. There were 17 sites of VMs, with nine patients diagnosed with oral VM at the Department of Dental and Oral Surgery, Tsukuba University Hospital. The medical records were retrospectively investigated to determine the site, hemangioma volume, polidocanol injection volume, and therapeutic effect. The volume of hemangiomas was calculated using magnetic resonance images. Based on the site, oral VMs were observed in the tongue, buccal mucosa, lips, and oral floor in eight, three, five, and one patients, respectively. The average size of the site was 3071 mm3. The average injection dose of polidocanol at one site was 2.86 mL, the average number of administrations was 1.6, and the response rate was 88.2%. No adverse events were observed. The median numerical rating scale scores were 2/10 (0–6/10) and 0/10 (0–1/10) the day after surgery and 1 week after surgery, respectively. Univariate regression analysis of the total dose in successful cases provided the following formula: 1.3 + 0.00025 × volume (mm3) (mg). Polidocanol sclerotherapy is an effective treatment method for oral VM.

Efficacy of foam sclerotherapy with polidocanol for the management of oral venous malformations

“…In 1944, Orbach ( 15 ) reported foam sclerotherapy as an ‘air-block technique’. Compared with conventional liquid sclerosing agents, foam sclerotherapy has been reported to be more effective at low concentrations and in small doses, thus reducing complications and enabling safe and effective treatment ( 4 ). The smaller the foam formed, the more effective the treatment ( 16 ).…”

“…Therefore, sclerotherapy has become a valuable alternative to the surgical resection of VMs in the maxillofacial region ( 3 ). Compared with conventional liquid sclerosing agents, foam sclerotherapy has been reported to be more effective at low concentrations and in small doses, thereby reducing complications and enabling safe and effective treatment ( 4 ). Although there have been some reports ( 5 , 6 ) on the effectiveness of polidocanol sclerotherapy without foam for VMs in the maxillofacial region, to the best of our knowledge, no study to date has evaluated the effectiveness and safety of foam sclerotherapy using only foam polidocanol for VMs in the oral and maxillofacial region.…”

Experience with 808-nm diode laser in the treatment of 47 cases of oral vascular anomalies

“…11 Several treatment options have been described for these conditions, including conventional surgery with or without adjunctive preoperative embolization, cryosurgery, and drug therapies (e.g., ethanolamine oleate and polidocanol). 5,33,34 However, these therapeutic approaches carry a risk of side effects such as scarring, pain, and bleeding. 5 Current advances in the use of high-power lasers allow oral health professionals to provide effective treatments with minimal side effects.…”

Evaluation of the Effects of Polidocanol Injection in the Treatment of Temporomandibular Joint Hypermobility - A Prospective Study

“…Polidocanol is a sclerosing agent that has been used widely in the treatment of varicose veins as well as low-flow venous malformations of the oral cavity. [ 26 , 27 ] It is an alkyl polyglycol ether of lauryl alcohol and was initially developed as a local anaesthetic in 1931. [ 28 ] Mild urticaria is the most general complication reported.…”